Please login to the form below

Not currently logged in
Email:
Password:

variant

This page shows the latest variant news and features for those working in and with pharma, biotech and healthcare.

MHRA approves second COVID-19 antibody treatment

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern. ... The approval coincides with new preclinical data released by GSK and Vir suggesting that Xevudy retains activity against key

Latest news

  • Annual COVID-19 jabs likely, says Pfizer head Annual COVID-19 jabs likely, says Pfizer head

    Pfizer is already working on an updated jab that could be ready within 100 days in light of the Omicron variant. ... Bourla said the company had taken the same action in response to the Beta and Delta variants of concern but that the tweaked vaccines had

  • Roche acquires test maker TIB Molbiol Roche acquires test maker TIB Molbiol

    virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants, said Roche.

  • Booster plans expanded to combat Omicron Booster plans expanded to combat Omicron

    Plans to accelerate and expand booster programmes against COVID-19 are being announced across the world as countries seek to counter the threat posed by the new variant of concern, Omicron.

  • US regulators set to approve oral antiviral against COVID-19 US regulators set to approve oral antiviral against COVID-19

    Merck developed molnupiravir with Ridgeback Biotherapeutics. “With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed,” said Dr Dean Y Li, ... In the light of the new variant of

  • COVID-19 vaccines against Omicron may be fast-tracked COVID-19 vaccines against Omicron may be fast-tracked

    With cases of Omicron appearing across the world, it is clear that travel bans will not be enough to prevent the spread of the new SARS-CoV-2 variant of concern. ... doesn’t work anymore, we can just come up with a variant vaccine, and not do a large

More from news
Approximately 17 fully matching, plus 189 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...